BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
5/15/2025 10:28:50 AM | Browse: 7 | Download: 40
 |
Received |
|
2024-09-10 17:58 |
|
Peer-Review Started |
|
2024-09-10 17:58 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2025-01-18 10:05 |
|
Revised |
|
2025-01-22 15:20 |
|
Second Decision |
|
2025-02-10 02:33 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2025-02-10 05:55 |
|
Articles in Press |
|
2025-02-10 05:55 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2025-02-24 07:03 |
|
Publish the Manuscript Online |
|
2025-05-15 10:28 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Letter to the Editor |
| Article Title |
Optimizing fluoropyrimidine therapy through dihydropyrimidine dehydrogenase polymorphism testing
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Arunkumar Krishnan |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Arunkumar Krishnan, Assistant Professor, MD, Department of Supportive Oncology, Atrium Health Levine Cancer, 1021 Morehead Medical Drive, Suite 70100, Charlotte, NC 28204, United States. dr.arunkumar.krishnan@gmail.com |
| Key Words |
Dihydropyrimidine dehydrogenase; Polymorphisms; Fluoropyrimidine; Drug adverse reactions; Drug toxicity; Economic evaluation; Genetic testing; Gastrointestinal cancers |
| Core Tip |
Dihydropyrimidine dehydrogenase (DPYD) polymorphism testing is important for minimizing severe fluoropyrimidine (FP)-related toxicities in cancer patients. This pharmacogenetic strategy promotes personalized dosing, improving patient safety and tolerability. A study by D’Amato et al assessed the prevalence of DPYD polymorphisms and their impact on FP tolerability in patients with gastrointestinal malignancies. However, it is important to tackle study limitations such as retrospective designs, variability in testing, and confounding factors and assess the cost-effectiveness of including DPYD testing in standard clinical practice. Future studies should broaden genetic screening, provide pre-treatment counseling, and establish standardized methodologies to improve clinical relevance. |
| Publish Date |
2025-05-15 10:28 |
| Citation |
<p>Krishnan A. Optimizing fluoropyrimidine therapy through dihydropyrimidine dehydrogenase polymorphism testing. <i>World J Gastrointest Oncol</i> 2025; 17(5): 101320</p> |
| URL |
https://www.wjgnet.com/1948-5204/full/v17/i5/101320.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v17.i5.101320 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
